Bibliometric study on hotspots and trends of immunotherapy for kidney cancer from 2014 to 2024. [PDF]
Guo Q, Nie Z.
europepmc +1 more source
Efficacy and safety of anti-VEGF/VEGFR monotherapy and combination with immune checkpoint inhibitors for advanced or metastatic renal cell carcinoma: a network meta-analysis. [PDF]
Duan M, Liu Y, Qiao K, Li Z, Zong D.
europepmc +1 more source
Metabolomic Profiling of Tyrosine Kinase Inhibitor-Induced Endothelial Dysfunction and Cardiovascular Toxicity. [PDF]
Singh G +12 more
europepmc +1 more source
Cardiac biomarkers in patients with renal cell carcinoma treated with immune checkpoint inhibitors. [PDF]
Chen YC +6 more
europepmc +1 more source
Sunitinib Impairs Oral Mucosal Healing Through Endoplasmic Reticulum Stress-Mediated Keratinocyte Dysfunction. [PDF]
Wang J +5 more
europepmc +1 more source
IMMUNOSARC II Master Trial: Phase II Study of Sunitinib and Nivolumab in Clear Cell Sarcoma Cohort. [PDF]
Martin-Broto J +27 more
europepmc +1 more source
Bayesian Evaluation of Treatment Effect of Avelumab Plus Axitinib for Advanced Renal Cell Carcinoma. [PDF]
Fukuokaya W +9 more
europepmc +1 more source
One size does not fit all: rethinking IO-TKI use in favorable-risk metastatic ccRCC. [PDF]
Valdés A, Grande E, Burotto M.
europepmc +1 more source
Sunitinib attenuates secondary injury via the regulation of peri-hematomal microglia at the acute phase of intracerebral hemorrhage. [PDF]
Zeng Y +8 more
europepmc +1 more source
Effect of Treatment Sequencing of Cytoreductive Nephrectomy on Overall Survival Outcomes in Patients Receiving Immunotherapy for Metastatic Renal Cell Carcinoma. [PDF]
Zamani A +7 more
europepmc +1 more source

